- Home
- SUJA vs CABA Comparison
SUJA vs CABA Comparison
Compare SUJA & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUJA | CABA |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 426.8M | 495.7M |
| IPO Year | 2026 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SUJA | CABA |
|---|---|---|
| Price | $10.07 | $3.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 264.0K | ★ 6.3M |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.71 | $1.26 |
| 52 Week High | $11.07 | $4.23 |
Technical Indicators
Market Signals| Indicator | SUJA | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 58.76 | 50.14 |
| Support Level | N/A | $3.12 |
| Resistance Level | $10.78 | $3.42 |
| Average True Range (ATR) | 0.88 | 0.22 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 59.75 | 63.48 |
Price Performance
Historical ComparisonAbout CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.